Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) (OPTIMAG)
Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR Monoclonal Antibody
Sponsor: Neptune
A NA clinical study on Metastatic Colorectal Cancer and Metastatic Head and Neck Cancer, this trial is ongoing. The trial is conducted by Neptune and has accumulated 10 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Nov 2023 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Nov 2021 — Nov 2023 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Nov 2021 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
May 2020 — Jan 2021 [monthly]
Recruiting NA
-
Aug 2019 — May 2020 [monthly]
Recruiting NA
-
Jun 2018 — Aug 2019 [monthly]
Recruiting NA
-
Oct 2017 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Oct 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Neptune
- Weprom
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Caen, France , Chambray-lès-Tours, France , La Roche-sur-Yon, France , Le Mans, France , Lorient, France , Nancy, France , Niort, France , Plérin, France , Pontivy, France , Tours, France and 1 more location